Cocrystal Pharma Stock Beta
| COCP Stock | USD 1.64 0.03 1.80% |
Cocrystal Pharma fundamentals help investors to digest information that contributes to Cocrystal Pharma's financial success or failures. It also enables traders to predict the movement of Cocrystal Stock. The fundamental analysis module provides a way to measure Cocrystal Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cocrystal Pharma stock.
Cocrystal | Beta |
Cocrystal Pharma Company Beta Analysis
Cocrystal Pharma's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Cocrystal Pharma Beta | 2.35 |
Most of Cocrystal Pharma's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cocrystal Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cocrystal Beta Driver Correlations
Understanding the fundamental principles of building solid financial models for Cocrystal Pharma is extremely important. It helps to project a fair market value of Cocrystal Stock properly, considering its historical fundamentals such as Beta. Since Cocrystal Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cocrystal Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cocrystal Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Cocrystal Pharma has a Beta of 2.347. This is 172.91% higher than that of the Pharmaceuticals sector and 68.85% higher than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
Cocrystal Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cocrystal Pharma's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cocrystal Pharma could also be used in its relative valuation, which is a method of valuing Cocrystal Pharma by comparing valuation metrics of similar companies.Cocrystal Pharma is currently under evaluation in beta category among its peers.
Cocrystal Pharma Institutional Holders
Institutional Holdings refers to the ownership stake in Cocrystal Pharma that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Cocrystal Pharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Cocrystal Pharma's value.| Shares | Bank Of America Corp | 2024-12-31 | 9 K | Ubs Group Ag | 2024-12-31 | 6.1 K | Tower Research Capital Llc | 2024-12-31 | 830 | Northwestern Mutual Wealth Management Co | 2024-12-31 | 817 | Clean Yield Group Inc | 2024-12-31 | 418 | Jpmorgan Chase & Co | 2024-12-31 | 259 | Mccormack Advisors International | 2024-12-31 | 237 | Nvwm, Llc | 2024-12-31 | 84.0 | Royal Bank Of Canada | 2024-12-31 | 51.0 | Vanguard Group Inc | 2024-12-31 | 275.7 K | Renaissance Technologies Corp | 2024-12-31 | 125.8 K |
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Cocrystal Pharma will likely underperform.
Cocrystal Fundamentals
| Return On Equity | -0.86 | ||||
| Return On Asset | -0.52 | ||||
| Current Valuation | 5.58 M | ||||
| Shares Outstanding | 10.17 M | ||||
| Shares Owned By Insiders | 31.85 % | ||||
| Shares Owned By Institutions | 6.99 % | ||||
| Number Of Shares Shorted | 14.37 K | ||||
| Price To Earning | 193.33 X | ||||
| Price To Book | 1.32 X | ||||
| Price To Sales | 92.45 X | ||||
| Gross Profit | (14.77 M) | ||||
| EBITDA | (19.37 M) | ||||
| Net Income | (17.98 M) | ||||
| Cash And Equivalents | 51.03 M | ||||
| Cash Per Share | 6.28 X | ||||
| Total Debt | 1.85 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 18.34 X | ||||
| Book Value Per Share | 1.25 X | ||||
| Cash Flow From Operations | (14.67 M) | ||||
| Short Ratio | 0.55 X | ||||
| Earnings Per Share | (1.84) X | ||||
| Target Price | 8.33 | ||||
| Number Of Employees | 12 | ||||
| Beta | 2.35 | ||||
| Market Capitalization | 16.73 M | ||||
| Total Asset | 31.26 M | ||||
| Retained Earnings | (315.91 M) | ||||
| Working Capital | 25.83 M | ||||
| Current Asset | 6.75 M | ||||
| Current Liabilities | 3.15 M | ||||
| Net Asset | 31.26 M |
About Cocrystal Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cocrystal Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cocrystal Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cocrystal Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Additional Tools for Cocrystal Stock Analysis
When running Cocrystal Pharma's price analysis, check to measure Cocrystal Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cocrystal Pharma is operating at the current time. Most of Cocrystal Pharma's value examination focuses on studying past and present price action to predict the probability of Cocrystal Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cocrystal Pharma's price. Additionally, you may evaluate how the addition of Cocrystal Pharma to your portfolios can decrease your overall portfolio volatility.